Equities research analysts expect Epizyme Inc (NASDAQ:EPZM) to report $2.83 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Epizyme’s earnings. The lowest sales estimate is $500,000.00 and the highest is $5.00 million. Epizyme posted sales of $9.70 million during the same quarter last year, which suggests a negative year over year growth rate of 70.8%. The firm is expected to report its next earnings results on Tuesday, February 25th.
On average, analysts expect that Epizyme will report full-year sales of $21.20 million for the current fiscal year, with estimates ranging from $19.51 million to $24.50 million. For the next fiscal year, analysts forecast that the company will report sales of $34.53 million, with estimates ranging from $5.18 million to $63.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Epizyme.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. Epizyme had a negative net margin of 468.53% and a negative return on equity of 49.38%. The company had revenue of $5.72 million during the quarter, compared to the consensus estimate of $5.50 million.
A number of equities analysts recently commented on the stock. BidaskClub downgraded shares of Epizyme from a “buy” rating to a “hold” rating in a research note on Wednesday. Cowen reaffirmed a “buy” rating and set a $18.00 price objective on shares of Epizyme in a report on Thursday, October 31st. ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a report on Thursday, October 31st. Finally, Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating and set a $11.00 price objective on the stock. in a report on Monday, October 21st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $17.50.
Several large investors have recently made changes to their positions in EPZM. Vanguard Group Inc. increased its stake in Epizyme by 29.9% in the 2nd quarter. Vanguard Group Inc. now owns 7,078,470 shares of the biopharmaceutical company’s stock valued at $88,835,000 after purchasing an additional 1,630,171 shares in the last quarter. BlackRock Inc. lifted its stake in Epizyme by 31.8% in the 2nd quarter. BlackRock Inc. now owns 6,440,597 shares of the biopharmaceutical company’s stock valued at $80,831,000 after buying an additional 1,552,216 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Epizyme during the 2nd quarter valued at $5,419,000. Voya Investment Management LLC increased its position in Epizyme by 133.3% during the third quarter. Voya Investment Management LLC now owns 651,683 shares of the biopharmaceutical company’s stock worth $6,722,000 after buying an additional 372,321 shares in the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in Epizyme during the second quarter worth $3,960,000. 86.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of EPZM traded down $0.33 during midday trading on Friday, reaching $15.57. The stock had a trading volume of 17,312 shares, compared to its average volume of 681,592. Epizyme has a 1-year low of $5.14 and a 1-year high of $17.00. The company’s fifty day simple moving average is $13.63 and its two-hundred day simple moving average is $12.84. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -9.06 and a beta of 2.58. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.90 and a quick ratio of 10.90.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Story: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.